A pancreas tumor derived organoid study: from drug screen to precision medicine

Yao, Jia; Yang, Ming; Atteh, Lawrence Lawer; Liu, Pinyan; Mao, Yongcui; Meng, Wenbo; Li, Xun

doi:10.1186/s12935-021-02044-1

Cited by 11 publications

(10 citation statements)

References 107 publications

(126 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Organoids have also successfully predicted the sensitivity of colorectal cancer ( 42 ), gastric cancer ( 43 ), ovarian cancer ( 44 ) and prostate cancer ( 45 ) to drugs. It appears at the present time that extracting samples from patient tumor tissues, creating and culturing organoids, exposing patient-derived tumor organoids to various drugs to find the best drug or drug combination to treat patients, revealing potential weaknesses of individual treatments based on gene mutation profiles and treatment responses of organoids and determining the next treatment route when first-line treatment is ineffective will become the ultimate mode of treatment for cancer ( 46 , 47 ) 1 .…”

Section: Discussionmentioning

confidence: 99%

Progress of research on tumor organoids: A bibliometric analysis of relevant publications from 2011 to 2021

et al. 2023

View full text Add to dashboard Cite

BackgroundResearch on tumor organoids has developed rapidly over the past 20 years, but a systematic analysis of current research trends is lacking. Researchers in the field need relevant references and knowledge of current research hot spots. Bibliometric analysis and visualization is a systematic method of acquiring an in-depth understanding of the status of research on tumor organoids.MethodsCiteSpace, VOSviewer and the Bibliometric Online Analysis Platform from the Web of Science Core Collection were used to analyze and predict publishing trends and research hot spots worldwide in the field of tumor organoids.ResultsA total of 3,666 publications on tumor organoids were retrieved, and 2,939 eligible articles were included in the final analysis. The number of publications has grown significantly, with the United States of America as the leading country for research on tumor organoids. Among journals, Cancers published the largest number of articles. Harvard Medical School published the highest number of articles among all institutions. The Chinese Academy of Sciences was ranked highest among all contributing institutions on the importance of their publications. A trend in multi-disciplinary collaboration was observed in studies on tumor organoids. Keywords indicated that the current research largely concentrated on optimizing the construction of organoid models to use for medication development and screening in the clinical setting, and to provide patients with individualized treatment for gastric cancer and colorectal cancer, which are newly emerging research hotspots. Gastric and colorectal cancers were the top two tumors that have received increasing attention and have become the focal points of recent studies.ConclusionThis study analyzed 2,939 publications covering the topic of tumor organoids. Although optimizing the construction of organoid models has always been a hot topic in this field, the application of tumor organoids to the development of medications and screenings will foster individualized treatment for patients, which is another emerging hot spot in this field of research.

show abstract

Section: Discussionmentioning

confidence: 99%

Progress of research on tumor organoids: A bibliometric analysis of relevant publications from 2011 to 2021

et al. 2023

View full text Add to dashboard Cite

show abstract

“…To take advantage of organoids, several biobanks have been established by academia and industry [37] . The Human Cancer Models Initiative (HCMI) is a representative database containing genomic data and patient information regarding various cancer-derived models, including organoids ( https://ocg.cancer.gov/programs/HCMI ).…”

Section: Patient-derived Model Systems Of Pdacmentioning

confidence: 99%

Challenges in genomic analysis of model systems and primary tumors of pancreatic ductal adenocarcinoma

Hyun

Park²

2022

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

“…Organoids are 3D cellular structures that recapitulate the identity and the cell type diversity of the organ from which they derive. Tumor organoids are novel ex vivo models that can mimic the characteristic of the original tumor in vitro , offering an additional strategy to personalizing therapeutic approaches and are being studied in pancreatic cancer ( 139 ).…”

Section: Organoids Recapitulating Tumor Primitive Characteristics Cou...mentioning

confidence: 99%

Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer

et al. 2022

View full text Add to dashboard Cite

The mainstay treatment for patients with immediate resectable pancreatic cancer remains upfront surgery, which represents the only potentially curative strategy. Nevertheless, the majority of patients surgically resected for pancreatic cancer experiences disease relapse, even when a combination adjuvant therapy is offered. Therefore, aiming at improving disease free survival and overall survival of these patients, there is an increasing interest in evaluating the activity and efficacy of neoadjuvant and perioperative treatments. In this view, it is of utmost importance to find biomarkers able to select patients who may benefit from a preoperative therapy rather than upfront surgical resection. Defined genomic alterations and a dynamic inflammatory microenvironment are the major culprits for disease recurrence and resistance to chemotherapeutic treatments in pancreatic cancer patients. Signal transduction pathways or tumor immune microenvironment could predict early recurrence and response to chemotherapy. In the last decade, distinct molecular subtypes of pancreatic cancer have been described, laying the bases to a tailored therapeutic approach, started firstly in the treatment of advanced disease. Patients with homologous repair deficiency, in particular with mutant germline BRCA genes, represent the first subgroup demonstrating to benefit from specific therapies. A fraction of patients with pancreatic cancer could take advantage of genome sequencing with the aim of identifying possible targetable mutations. These genomic driven strategies could be even more relevant in a potentially curative setting. In this review, we outline putative predictive markers that could help in the next future in tailoring the best therapeutic strategy for pancreatic cancer patients with a potentially curable disease.

show abstract

A pancreas tumor derived organoid study: from drug screen to precision medicine

Cited by 11 publications

References 107 publications

Progress of research on tumor organoids: A bibliometric analysis of relevant publications from 2011 to 2021

Progress of research on tumor organoids: A bibliometric analysis of relevant publications from 2011 to 2021

Challenges in genomic analysis of model systems and primary tumors of pancreatic ductal adenocarcinoma

Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer

Contact Info

Product

Resources

About